ALX Oncology
ALXO
96 hedge funds and large institutions have $622M invested in ALX Oncology in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 32 increasing their positions, 34 reducing their positions, and 21 closing their positions.
23% more call options, than puts
Call options by funds: $444K | Put options by funds: $361K
0.95% more ownership
Funds ownership: 89.61% → 90.56% (+0.95%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 34
11% less funds holding
Funds holding: 108 → 96 (-12)
20% less capital invested
Capital invested by funds: $780M → $622M (-$158M)
52% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$11.8M |
| 3 |
O
OrbiMed
New York
|
+$7.07M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.67M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$4.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$19.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.7M |
| 3 |
Two Sigma Investments
New York
|
-$4.13M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$2.29M |
| 5 |
Millennium Management
New York
|
-$1.84M |
ALXO Hedge Fund Activity: Q1 2022 in Review
96 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q1 2022, worth a combined $622M — down 20% from $780M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ALXO and 10 opened new positions — a net loss of 11 holders — while 34 trimmed existing stakes and 32 added.
The largest buyer was Fidelity Investments, adding an estimated $16.5M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $19.8M sold.
- 96 institutional investors held ALX Oncology (ALXO) as of Q1 2022, down from 108 in Q4 2021.
- Funds reported $622M of ALX Oncology stock for Q1 2022, down 20% quarter-over-quarter.
- 10 funds opened new ALX Oncology positions in Q1 2022 and 21 closed out, a net change of -11 holders.
- The largest ALX Oncology buyer in Q1 2022 was Fidelity Investments, an estimated $16.5M added.
- The largest ALX Oncology seller in Q1 2022 was Janus Henderson Group, an estimated $19.8M sold.
Based on aggregated 13F filings for Q1 2022.